New drug cocktail shows promise for tough-to-treat hodgkin lymphoma
NCT ID NCT05922904
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a combination of four drugs (brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach can control the disease while reducing side effects. Participants have stage II with bulky disease or stage III/IV classic Hodgkin lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.